Skyrizi snags FDA approval for moderate to severe UC; first IL-23 approved for UC, CD

The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, making it the first interleukin-23 specific inhibitor approved for both UC and Crohn’s disease, AbbVie reported.
Skyrizi (risankizumab, AbbVie) is now approved for four indications across immune-mediated inflammatory diseases, including IBD, plaque psoriasis and psoriatic arthritis, according to a company press release.
“When treating patients with ulcerative colitis, it’s important to prioritize both early and sustained clinical remission as well as endoscopic improvement,”

The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, making it the first interleukin-23 specific inhibitor approved for both UC and Crohn’s disease, AbbVie reported.
Skyrizi (risankizumab, AbbVie) is now approved for four indications across immune-mediated inflammatory diseases, including IBD, plaque psoriasis and psoriatic arthritis, according to a company press release.
“When treating patients with ulcerative colitis, it’s important to prioritize both early and sustained clinical remission as well as endoscopic improvement,”